americanpharmaceuticalreviewMarch 05, 2021
Tag: Chimerix , COVID-19 , DSTAT , Cantex
Cantex Pharmaceuticals announced Chimerix, worldwide licensee of Cantex's DSTAT investigational product, has reported promising results of the first cohort of patients hospitalized with COVID-19-associated Acute Lung Injury (ALI), suggesting that dociparstat sodium (DSTAT) may accelerate recovery from ALI, as well as mitigate thrombotic events in such patients.
"We are very pleased that our ongoing collaboration under our license agreement with Chimerix has led to early promising results in the important setting of the treatment of hospitalized patients with COVID-19 infection. In the context of the Joint Development Committee established at the time of the license agreement, Cantex will continue to support the development of DSTAT for ALI, acute myeloid leukemia (AML), and other important indications," Stephen G. Marcus, M.D., CEO of Cantex, said.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: